Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.56 |
| ▸ | F3 | P13726 | 1/20 | 0.56 |
| ▸ | PRKAB2 | O43741 | 17/20 | 0.55 |
| ▸ | PRKAG1 | P54619 | 17/20 | 0.55 |
| ▸ | PRKAA2 | P54646 | 17/20 | 0.55 |
| ▸ | PRKAA1 | Q13131 | 17/20 | 0.55 |
| ▸ | PRKAG3 | Q9UGI9 | 17/20 | 0.55 |
| ▸ | PRKAG2 | Q9UGJ0 | 17/20 | 0.55 |
| ▸ | PRKAB1 | Q9Y478 | 17/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3104933 | 0.93 | PRKAB2 (0.59) | F7F3PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL30416918 | 0.85 | PRKAB2 (0.59) | F7F3PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL17429453 | 0.85 | PRKAB2 (0.59) | F7F3PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL23612266 | 0.85 | PRKAG1 (0.66) | F7F3PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL10478126 | 0.84 | KDM4E (0.60) | F7F3PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL17417668 | 0.79 | PRKAB2 (0.58) | F7F3PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL31375035 | 0.79 | PRKAB2 (0.55) | F7F3PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL23167845 | 0.79 | PRKAB2 (0.54) | F7F3PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL6897941 | 0.79 | PRKAB2 (0.55) | F7F3PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL17417592 | 0.77 | CYP2C19 (0.52) | F7F3PRKAB2PRKAG1PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118515600-A | Isoindoline compound and medical application thereof | 中国科学院上海药物研究所 | 2024-08-20 | — | — | CN | disclosed |
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-27 | — | — | US | disclosed |
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-27 | — | — | US | disclosed |
| WO-2021138434-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2021-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | F7 4066/4885F3 4163/4885PRKAB2 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.